Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01459159 · ClinicalTrials.gov registry record · Phase 2
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
A Phase 2 study, sponsored by Telik.
- Terminated
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
NCT01459159: Clinical Trial Phase 2 study, sponsored by Telik.
NCT01459159 is a Phase 2 study that was terminated before completion, run by Telik. The registered enrollment target is 162 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (22% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01459159, a Phase 2 study, was terminated before completion, sponsored by Telik.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
Study Summary
This is a multicenter, single arm open label Phase 2b Study of oral ezatiostat (Telintra®) in Patients who are RBC tranfusion dependent, Low to INT-1 IPSS risk, non-del (5q) Myelodysplastic Syndrome (MDS).
Primary Outcome
Hematologic Improvement response will be assessed per the IWG MDS response criteria (2006)
Interventions
- DRUG ezatiostat hydrochloride (Telintra®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
Why NCT01459159 stopped before completion
NCT01459159 is an interventional study that assigns participants to a tested intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (22% higher).
The record links to 0 conditions, and to 1 intervention - of which ezatiostat hydrochloride (Telintra®) is the first listed.
NCT01459159 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01459159 about?
NCT01459159 is a clinical study titled "Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome". This is a multicenter, single arm open label Phase 2b Study of oral ezatiostat (Telintra®) in Patients who are RBC tranfusion dependent, Low to INT-1 IPSS risk, non-del (5q) Myelodysplastic Syndrome (MDS).
What is the current status of trial NCT01459159?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2011-10. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01459159?
The interventions under investigation include: ezatiostat hydrochloride (Telintra®) (DRUG).
Who is sponsoring clinical trial NCT01459159?
This trial is sponsored by Telik, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01459159's enrollment target sits among peer trials
162 418th of 2000 higher than 1,579 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02347111 · 162 participants · Phase 4
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- NCT02610426 · 162 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
- NCT05040711 · 162 participants · NA
mHealth Mindfulness With Patients With Serious Illness and Their Caregivers
- NCT05514717 · 162 participants · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia